SwishX has introduced a groundbreaking Agentic AI platform tailored specifically for the pharmaceutical and medtech sectors, backed by $2.2 million in seed funding.
The Bengaluru-based startup aims to revolutionize commercial operations, focusing on sales, marketing, tenders, contracts, and distribution. With the recent funding from investors like Powerhouse Ventures and Blume Ventures, SwishX is targeting over 100 enterprise clients and anticipates achieving $5 million in annual recurring revenue by the end of FY2026-27. The company is also planning to expand its presence in various global markets, including Latin America and Southeast Asia.
SwishX's platform addresses longstanding inefficiencies in the pharmaceutical and medical device industries, where many businesses still depend on outdated tools like spreadsheets and manual workflows. The AI-driven solution promises to enhance revenue outcomes by as much as 30% through improved visibility into operations, such as public tenders and doctor engagement.
According to CEO Dushyant Sapre, the transformation in the pharmaceutical sector will stem from advancements in market execution rather than laboratory innovations. By leveraging AI agents, companies can achieve autonomous, real-time decision-making, significantly improving their operational effectiveness.